Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02452528
- Locations
- 🇺🇸
Kaiser Permanente, San Francisco, California, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Univ. Of Miami School Of Medicine/Center For Liver Diseases, Miami, Florida, United States
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT02363946
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇦🇺Nucleus Network Ltd, Melbourne, Victoria, Australia
🇩🇪Universitatsklinikum des Saarlandes, Homburg, Germany
Study of ARC-520 in Patient With Chronic Hepatitis B Virus
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: ARC-520 Injection
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Registration Number
- NCT02349126
- Locations
- 🇦🇺
Nucleus Network Ltd, Melbourne, Victoria, Australia
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02065336
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇭🇰Queen Mary Hospital, Pokfulam, Hong Kong
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01872065
- Locations
- 🇦🇺
Nucleus Network Ltd., Melbourne, Victoria, Australia